Table 1.
Baseline characteristics
| Implementation group (n = 119) | Control group (n = 93) | Total (n = 212) | |
|---|---|---|---|
| Sex (male)—n (%) | 63 (52.94) | 51 (54.84) | 114 (53.77) |
| Age (years) | |||
| mean | 72.14 | 69.65 | 71.21 |
| SD | 10.67 | 14.23 | 12.20 |
| Amiodarone—n (%) | 3 (2.52) | 4 (4.26) | 7(3.30) |
| Alcohol intake (units per day)—n (%) | |||
| < 1 | 62 (52.99) | 62(66.67) | 122(58.10) |
| 1–5 | 34(29.06) | 21(22.34) | 57(27.14) |
| 6–14 | 10(8.55) | 7(7.45) | 19(9.05) |
| 15–21 | 9(7.69) | 1(1.06) | 10(4.76) |
| 22–49 | 2(1.71) | 2(2.13) | 4(1.90) |
| missing | 2 | 2 | |
| Smoking status—n (%) | |||
| Current | 19(16.10) | 14(14.89) | 33(15.64) |
| Previous | 39(33.05) | 37(39.78) | 76(36.02) |
| Never | 60(50.85) | 42(44.68) | 102(48.34) |
| Missing | 1 | 1 | |
| Indication—n (%) | |||
| AF | 111 (93.28) | 56(59.57) | 167(78.77) |
| DVT | 4(3.36) | 17(18.09) | 21(9.91) |
| PE | 4(3.36) | 20(21.51) | 24(11.32) |
| CYP2C9*2—n (%) | |||
| *1/*1 | 91 (76.47) | ||
| *1/*2 | 27(22.69) | ||
| *2/*2 | 1(0.84) | ||
| CYP2C9*3—n (%) | |||
| *1/*1 | 105(88.24) | ||
| *1/*3 | 14(11.76) | ||
| *3/*3 | 0 (0.00) | ||
| VKORC1—n (%) | |||
| G/G | 49(41.18) | ||
| G/A | 57(47.90) | ||
| A/A | 13(10.92) | ||
| Target INR range—n (%) | |||
| 2–3 | 115(96.64) | 92(98.93) | 207(97.64) |
| 2–2.5 | 0(0.00) | 1(1.06) | 1(0.47) |
| 2.5–3.5 | 3(2.52) | 0(0.00) | 3(1.42) |
| 1.8–3.2 | 1(0.84) | 0(0.00) | 1(0.47) |